Prevention of experimental autoimmune uveoretinitis by infusions of human therapeutic intravenous immunoglobulins in rats.
Saoudi
A
A
INSERM U28, Hopital Broussais, Paris, France.
Hurez
V
V
De Kozak
Y
Y
Kuhn
J
J
Kaveri
S V
SV
Kazatchkine
M D
MD
Druet
P
P
Bellon
B
B
D000818:Animals; D000941:Antigens / Q000008:administration & dosage; D000961:Antilymphocyte Serum / Q000494:pharmacology; D019393:Arrestin; D001327:Autoimmune Diseases / Q000209:etiology / Q000517:prevention & control*; D005136:Eye Proteins / Q000008:administration & dosage; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000494:pharmacology*; D007165:Immunosuppression Therapy; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000096:biosynthesis; D008213:Lymphocyte Activation; D008297:Male; D051381:Rats; D011914:Rats, Inbred BN; D011917:Rats, Inbred Lew; D012173:Retinitis / Q000209:etiology / Q000517:prevention & control*; D014605:Uveitis / Q000209:etiology / Q000517:prevention & control*
D000941:Antigens; D000961:Antilymphocyte Serum; D019393:Arrestin; D005136:Eye Proteins; D016756:Immunoglobulins, Intravenous; D007376:Interleukin-2